Evidence map›Paper›PMID 26856847›Full record

ArticleAntimicrobial agents and chemotherapy2016

Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii.

Mya Thandar, Rolf Lood, Benjamin Y Winer, Douglas R Deutsch, Chad W Euler, Vincent A Fischetti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Designing of a novel chimeric antimicrobial peptide againstResearch in pharmaceutical sciences · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mya ThandarLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA.
Rolf LoodLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA.
Benjamin Y WinerLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA.
Douglas R DeutschLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA.
Chad W EulerLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA.
Vincent A FischettiLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA vaf@rockefeller.edu.

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007388 · NIGMS · PRINCETON UNIVERSITY · PI CRISTEA, ILEANA M. · 1985 to 2022
$27.4M
NIGMS NIH HHS T32 GM007388
6 · The paper itself

Abstract

Acinetobacter baumannii is a Gram-negative bacterial pathogen responsible for a range of nosocomial infections. The recent rise and spread of multidrug-resistant A. baumannii clones has fueled a search for alternative therapies, including bacteriophage endolysins with potent antibacterial activities. A common feature of these lysins is the presence of a highly positively charged C-terminal domain with a likely role in promoting outer membrane penetration. In the present study, we show that the C-terminal amino acids 108 to 138 of phage lysin PlyF307, named P307, alone were sufficient to kill A. baumannii (>3 logs). Furthermore, P307 could be engineered for improved activity, the most active derivative being P307SQ-8C (>5-log kill). Both P307 and P307SQ-8C showed high in vitro activity against A. baumannii in biofilms. Moreover, P307SQ-8C exhibited MICs comparable to those of levofloxacin and ceftazidime and acted synergistically with polymyxin B. Although the peptides were shown to kill by disrupting the bacterial cytoplasmic membrane, they did not lyse human red blood cells or B cells; however, serum was found to be inhibitory to lytic activity. In a murine model of A. baumannii skin infection, P307SQ-8C reduced the bacterial burden by ∼2 logs in 2 h. This study demonstrates the prospect of using peptide derivatives from bacteriophage lysins to treat topical infections and remove biofilms caused by Gram-negative pathogens.

Indexed as

Acinetobacter baumanniiAnimalsAnti-Bacterial AgentsAnti-Infective AgentsBiofilmsCeftazidimeDrug Resistance, Multiple, BacterialFemaleLevofloxacinMiceMicrobial Sensitivity TestsPeptidesPolymyxin BProtein Structure, SecondaryAnti-Bacterial AgentsAnti-Infective AgentsCeftazidimeLevofloxacinPeptidesPolymyxin B

Identifiers

PMID26856847
PMCPMC4862495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.